Gut Fungus Battle Reveals Dietary Key to Taming IBD Inflammation
A newly identified gut fungus suppresses Candida overgrowth via amino acid competition — and restricting dietary threonine reduces colitis in mice.
Summary
Researchers discovered that a gut fungus called Cladosporium tenuissimum can suppress Candida albicans overgrowth by competing for the amino acid ornithine in the intestine. However, Candida can escape this control by feeding on threonine instead, worsening intestinal inflammation. The common gut bacterium Bacteroides fragilis fuels this escape by producing threonine, creating a bacterial-fungal alliance that promotes colitis. Crucially, when mice were fed a low-threonine diet, Candida-driven colitis was significantly reduced. This study maps a previously unknown cross-kingdom metabolic network — spanning bacteria, fungi, and diet — that governs gut inflammatory outcomes, pointing toward novel dietary and therapeutic strategies for inflammatory bowel disease.
Detailed Summary
Inflammatory bowel disease (IBD) affects millions worldwide, yet the role of fungi in driving or resolving intestinal inflammation has been largely overlooked. Most microbiome research focuses on bacteria, leaving the fungal kingdom — and its interactions with bacterial neighbors — poorly understood. This study addresses that gap with significant implications for IBD treatment.
Researchers from Shanghai Jiao Tong University investigated how fungal-bacterial metabolic interactions influence Candida albicans behavior and colitis severity. Using mouse models of colitis along with microbial and metabolic analyses, they screened gut fungi for disease-modifying activity and probed the mechanistic underpinnings of their findings.
The team identified Cladosporium tenuissimum as a gut fungus capable of powerfully alleviating colitis. It does so by outcompeting Candida albicans for the amino acid ornithine, effectively starving the pathobiont. However, Candida can evade this suppression by switching its nutrient source to threonine, a different amino acid that enables its continued growth and inflammatory activity. The gut bacterium Bacteroides fragilis plays a critical enabling role by producing threonine, creating a pro-inflammatory bacterial-fungal metabolic axis. When dietary threonine was restricted in mice, Candida-driven colitis was markedly attenuated.
These findings reframe gut inflammation as the product of intricate cross-kingdom metabolic negotiations, not simply bacterial dysbiosis. For IBD patients, this raises the possibility that targeted dietary modification — specifically threonine restriction — or therapeutic administration of C. tenuissimum could reduce Candida-fueled intestinal inflammation.
Several caveats apply. The study was conducted primarily in mouse models, and translation to human IBD patients requires clinical validation. The summary is based on the abstract only, so mechanistic depth and full methodology cannot be fully evaluated. Dietary threonine restriction carries its own nutritional trade-offs that would need careful management in clinical settings.
Key Findings
- Cladosporium tenuissimum suppresses Candida albicans by competing for the amino acid ornithine in the gut.
- Candida escapes fungal control by switching to threonine as a nutrient source, worsening colitis.
- Bacteroides fragilis fuels Candida overgrowth by supplying threonine, linking bacterial and fungal pathobiology.
- Dietary threonine restriction significantly reduces Candida-driven colitis in mouse models.
- A cross-kingdom metabolic network — bacteria, fungi, and diet — governs intestinal inflammatory outcomes.
Methodology
The study used mouse colitis models to test fungal effects on intestinal inflammation and employed microbial, metabolomic, and mechanistic analyses to map amino acid-based interactions between C. tenuissimum, C. albicans, and B. fragilis. Dietary threonine restriction was tested as an intervention in vivo. Full methodology is not accessible as the summary is based on the abstract only.
Study Limitations
All experimental interventions were conducted in mouse models, and human clinical validation is needed before dietary or microbial recommendations can be made. The summary is based on the abstract only, limiting full assessment of methodology, effect sizes, and statistical rigor. Dietary threonine restriction may have broader nutritional consequences requiring careful clinical management.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.